Papaparaskevas J, Tzouvelekis LS, Tsakris A, Pittaras TE, Legakis NJ, Hellenic Tigecycline Study Group: In vitro activity of
tigecycline Luminespib in vivo against 2423 clinical isolates and comparison of the available interpretation breakpoints. Diagn Microbiol Infect Dis 2010,66(2):187–194.PubMedCrossRef 238. Giamarellou H, Poulakou G: Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 2009,69(14):1879–1901.PubMedCrossRef 239. Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J, Scatina J: Metabolism, excretion, and pharmacokinetics of [14C] tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 2007,35(9):1543–1553.PubMedCrossRef 240. Gladman MA, Knowles CH, Gladman LJ, Payne JG: Intra-operative culture in appendicitis: traditional practice
challenged. Ann R Coll Surg Engl 2004,86(3):196–201.PubMedCrossRef 241. Davies HO, Alkhamesi NA, Dawson PM: Peritoneal fluid culture in appendicitis: review in changing times. Int J Surg 2010,8(6):426–429.PubMedCrossRef 242. Sartelli M, Catena F, Ansaloni L, Leppäniemi A, Taviloglu K, van Goor H, Viale P, Lazzareschi DV, de Werra C, Marrelli D, Colizza S, Scibé R, Alis H, Torer N, Navarro S, Catani M, Kauhanen S, Augustin G, Sakakushev B, Massalou Selleckchem EGFR inhibitor D, Pletinckx P, Kenig J, Di Saverio S, Guercioni G, Rausei S, Laine Parvulin S, Major P, Skrovina M, Angst E, Pittet O, Gerych I, Tepp J, Weiss G, Vasquez G, Vladov N, Tranà C, Vettoretto N, Delibegovic S, Dziki A, Giraudo G, Pereira J, Poiasina E, Tzerbinis H, Hutan M, Vereczkei A, Krasniqi A, Seretis C, Diaz-Nieto R, Mesina C, Rems M, Campanile FC, Agresta F, Coletta P, Uotila-Nieminen M, Dente M, Bouliaris K, Lasithiotakis K, Khokha V, et al.: Complicated intra-abdominal infections in Europe: preliminary data from the first three months of the CIAO study. World J Emerg Surg 2012,7(1):15.PubMedCrossRef 243. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, Dupont H: Clinical and microbiological
profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009,63(4):785–794.PubMedCrossRef 244. Seguin P, Laviolle B, Chanavaz C, Donnio PY, Gautier-Lerestif AL, Campion JP, Mallédant Y: Factors associated with multidrug-resistant bacteria in secondary peritonitis: impact on antibiotic therapy. Clin Microbiol Infect 2006,12(10):980–985.PubMedCrossRef 245. Gaieski DF, Mikkelsen ME, Band RA, Pines JM, Massone R, Furia FF, Shofer FS, Goyal M: Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal-directed therapy was initiated in the emergency department. Crit Care Med 2010,38(4):1045–1053.PubMedCrossRef 246.